Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 202

1.

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K.

Leukemia. 2016 Nov 29. doi: 10.1038/leu.2016.299. [Epub ahead of print]

PMID:
27774990
2.

Iron rusting in the mitochondria?

Gattermann N.

Blood. 2016 Oct 13;128(15):1907-1908. No abstract available.

PMID:
27737844
3.

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P.

J Clin Oncol. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118.

PMID:
27354480
4.

Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.

Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hänel M, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL)..

Ann Hematol. 2016 Sep;95(9):1399-410. doi: 10.1007/s00277-016-2730-y.

PMID:
27334946
5.

γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.

Görtzen J, Hunka LM, Vonnahme M, Praktiknjo M, Kaifie A, Fimmers R, Jansen C, Heine A, Lehmann J, Goethert JR, Gattermann N, Goekkurt E, Platzbecker U, Brossart P, Strassburg CP, Brummendorf TH, Koschmieder S, Wolf D, Trebicka J.

Medicine (Baltimore). 2016 May;95(20):e3355. doi: 10.1097/MD.0000000000003355.

6.

Causes of death in 2877 patients with myelodysplastic syndromes.

Nachtkamp K, Stark R, Strupp C, Kündgen A, Giagounidis A, Aul C, Hildebrandt B, Haas R, Gattermann N, Germing U.

Ann Hematol. 2016 May;95(6):937-44. doi: 10.1007/s00277-016-2649-3.

PMID:
27025507
7.

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.

Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL)..

J Hematol Oncol. 2016 Mar 5;9:18. doi: 10.1186/s13045-016-0242-9.

8.

New insights into transfusion-related iron toxicity: Implications for the oncologist.

Porter JB, de Witte T, Cappellini MD, Gattermann N.

Crit Rev Oncol Hematol. 2016 Mar;99:261-71. doi: 10.1016/j.critrevonc.2015.11.017. Review.

PMID:
26806144
9.

Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).

Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U, Nolte F, Götze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U.

Leukemia. 2016 Jul;30(7):1580-2. doi: 10.1038/leu.2015.340. No abstract available.

PMID:
26668126
10.

Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide.

Beier F, Masouleh BK, Buesche G, Ventura Ferreira MS, Schneider RK, Ziegler P, Wilop S, Vankann L, Gattermann N, Platzbecker U, Giagounidis A, Götze KS, Nolte F, Hofmann WK, Haase D, Kreipe H, Panse J, Blasco MA, Germing U, Brümmendorf TH.

Leuk Res. 2015 Sep 21. pii: S0145-2126(15)30380-5. doi: 10.1016/j.leukres.2015.09.003. [Epub ahead of print]

PMID:
26427727
11.
12.

In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.

Lauseker M, Schemenau J, Strupp C, Kündgen A, Gattermann N, Hasford J, Germing U.

Br J Haematol. 2015 Sep;170(5):687-93. doi: 10.1111/bjh.13496.

PMID:
25960152
13.

Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.

Hejazi M, Manser AR, Fröbel J, Kündgen A, Zhao X, Schönberg K, Germing U, Haas R, Gattermann N, Uhrberg M.

Haematologica. 2015 May;100(5):643-52. doi: 10.3324/haematol.2014.118679.

14.

Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.

Schemenau J, Baldus S, Anlauf M, Reinecke P, Braunstein S, Blum S, Nachtkamp K, Neukirchen J, Strup C, Aul C, Haas R, Gattermann N, Germing U.

Eur J Haematol. 2015 Sep;95(3):181-9. doi: 10.1111/ejh.12512. Review.

PMID:
25600827
15.

Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias.

Schuler E, Schroeder M, Neukirchen J, Strupp C, Xicoy B, Kündgen A, Hildebrandt B, Haas R, Gattermann N, Germing U.

Leuk Res. 2014 Dec;38(12):1413-9. doi: 10.1016/j.leukres.2014.09.003.

PMID:
25444076
16.

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.

Santini V, Prebet T, Fenaux P, Gattermann N, Nilsson L, Pfeilstöcker M, Vyas P, List AF.

Leuk Res. 2014 Dec;38(12):1381-91. doi: 10.1016/j.leukres.2014.09.008. Review.

17.

Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia.

Sonnet M, Claus R, Becker N, Zucknick M, Petersen J, Lipka DB, Oakes CC, Andrulis M, Lier A, Milsom MD, Witte T, Gu L, Kim-Wanner SZ, Schirmacher P, Wulfert M, Gattermann N, Lübbert M, Rosenbauer F, Rehli M, Bullinger L, Weichenhan D, Plass C.

Genome Med. 2014 Apr 30;6(4):34. doi: 10.1186/gm551.

18.

When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?

Steensma DP, Gattermann N.

Best Pract Res Clin Haematol. 2013 Dec;26(4):431-44. doi: 10.1016/j.beha.2013.09.009. Review. Erratum in: Best Pract Res Clin Haematol. 2014 Jun;27(2):e1.

PMID:
24507819
19.

The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.

Zipperer E, Tanha N, Strupp C, Kündgen A, Nachtkamp K, Neukirchen J, Hildebrandt B, Haas R, Gattermann N, Germing U.

Haematologica. 2014 Mar;99(3):e31-2. doi: 10.3324/haematol.2013.101055. No abstract available.

20.

Myelodysplastic syndromes: diagnosis, prognosis, and treatment.

Germing U, Kobbe G, Haas R, Gattermann N.

Dtsch Arztebl Int. 2013 Nov 15;110(46):783-90. doi: 10.3238/arztebl.2013.0783. Review.

Items per page

Supplemental Content

Loading ...
Support Center